CBT Stock Analysis — Cabot Corporation
Sector: Chemicals
AI Verdict
CBT trades at 11.8x next year's earnings while analysts expect 9.0% EPS growth — that's cheap for a specialty chemicals firm with process technology and contract moats, but the market is clearly skeptical that growth will return soon.
Competitive Moat
Cabot specializes in performance materials like carbon black, which are critical inputs for tires, batteries, and specialty plastics. Its moat comes from proprietary process technology and long-term supply contracts with industrial customers, making its position defensible against commodity price swings.
Summary
CBT stands out for its ability to maintain profitability in a tough chemicals market, with a forward P/E of 11.8x and 9.0% expected EPS growth.
Where It Stands
CBT delivered a -9.6% revenue decline last year but trades at just 11.8x next year's earnings, a discount to the chemicals sector median of ~16x.
Key Metrics
- Trailing P/E: 12.8x
- Forward P/E: 11.8x
- PEG Ratio: 1.43
- Earnings Growth: +0.1%
- Revenue Growth: -0.1%
- Dividend Yield: 0.02%
- 52-Week High: $85.27
- 52-Week Low: $58.33
Analyst Consensus
1 Buy · 6 Hold · 6 Sell (13 analysts)
Bull Case
With analysts forecasting 9.0% EPS growth and a forward P/E of 11.8x, the stock is priced cheaply for a company with defensible industrial contracts.
Bear Case
If the P/E reverts to 10x due to ongoing revenue declines, the stock could lose another 15% from current valuation levels.
Catalyst to Watch
Watch for quarterly earnings updates to see if revenue stabilizes or continues to slide, as a return to growth would justify the current multiple.